TORONTO, July 5, 2012 /CNW/ - Clinical Trials Ontario (CTO) officially
launched at the 2012 BIO International Convention, the global event for
biotechnology. The pharmaceutical industry welcomed the announcement as
a boost to drug development in Ontario.
Clinical Trials Ontario has been created as a province-wide entity to make Ontario the preferred location for global clinical trials activity
while maintaining the highest ethical standards.
While Clinical Trials Ontario's goal is to comprehensively make Ontario
more competitive in the global clinical trials marketplace, its initial
strategic approach is to streamline the ethics review and contract
approval processes for industry-driven multi-site clinical trials in
Creating Clinical Trials Ontario satisfies one of the strategic
initiatives under the government's Life Sciences Commercialization Strategy to help position Ontario as one of the world's leading life sciences
jurisdictions. This will ensure cutting-edge healthcare discoveries and
products are developed and nurtured in Ontario — keeping and creating
high-value jobs in Ontario and providing Ontarians with early access to
innovative approaches to health care through investigational drugs,
devices and services.
This approach will also reduce duplication, shorten study start-up time, provide the highest quality of review and ensure the highest standard of patient safety while increasing patient access to investigational therapies.
Given the importance of the governance structure for Clinical Trials
Ontario and its relationship to industry and academia, its Board of
Directors was also announced. To access a complete list of the members
of the CTO Board of Directors, click on CTO Board of Directors.
"Ontario is already a leader in bio-sciences and has one of the largest
clusters in North America. This initiative is about sustaining the
momentum we've built up and supporting a cutting-edge industry and good
— Brad Duguid, Minister of Economic Development & Innovation
"In addition to helping Ontario become a strong competitor in the global
industry-driven clinical trials market and providing better access to
patients for innovative therapies, Clinical Trials Ontario will draw
more industry investment to Ontario."
— Ronald Heslegrave, Executive Director, Clinical Trials Ontario
"We believe that the CTO will be a very important asset to Ontario in
attracting Clinical Trials and the Research and Development investment
that comes with it. Through the creation and funding of CTO, the
Ontario government has shown that it understands the high level of
global competition for the placement of Clinical Trials and has taken
steps to be a world class player in this arena.
— Nita Arora, Head of Clinical Operations, North America, Hoffmann-La
More than 5,200 clinical trials are underway in Ontario at any given
Every year, public and private researchers in Ontario conduct $13.5
billion in R&D across all sectors.
Currently, Ontario invests more than $500 million annually in basic and
translational life sciences R&D.
The private sector invests almost $700 million yearly in applied health
research, including clinical trials.
More than a million square feet and $1 billion in new research
facilities have been completed in Ontario since 2005.
LEARN MORE ABOUT:
SOURCE Clinical Trials Ontario (CTO)
For further information:
Ronald J. Heslegrave
Executive Director, Clinical Trials Ontario
655 Bay Street, Suite 600,
Toronto, Ontario M5G 2K4
T: 647.847.3129 E: email@example.com